secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2021-08-16T23:59:59+00:00
Accession:  0001193125-21-247855
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC appoints Steven Hoerter as director; Peter Svennilson resigns from board
-----------------------------------------------------------------------------

- Steven L. Hoerter, CEO of Deciphera Pharmaceuticals, appointed as Class II director effective Aug 13, 2021; will serve on Audit Committee.
- Peter Svennilson resigned voluntarily as part of planned reduction of public board commitments; had served over six years since TCG's founding investment.
- New director Hoerter receives annual retainer of $35,000 plus $7,500 for Audit Committee; granted option for 33,250 shares vesting monthly over 3 years.
- Lease amendment expands facility by ~340 sq ft, extends term to May 2028, and landlord contributes $1,514,835 toward improvements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312521247855/0001193125-21-247855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312521247855/d127312d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-247855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer